The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
about
Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.Anticancer activity profiling of parthenolide analogs generated via P450-mediated chemoenzymatic synthesis.Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance.HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
P2860
The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
The Intelence aNd pRezista Onc ...... reatment-experienced subjects.
@en
type
label
The Intelence aNd pRezista Onc ...... reatment-experienced subjects.
@en
prefLabel
The Intelence aNd pRezista Onc ...... reatment-experienced subjects.
@en
P2093
P2860
P356
P1433
P1476
The Intelence aNd pRezista Onc ...... reatment-experienced subjects.
@en
P2093
D Anderson
INROADS study investigators
M Ramgopal
T N Kakuda
P2860
P304
P356
10.1111/HIV.12211
P577
2015-01-14T00:00:00Z